Luke Roy Georg Pike MD DPhil
Assistant Attending / Assistant Professor
Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Pike
Dr. Luke Pike is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Boston Children's Hospital. He received his medical degree from Yale School of Medicine and has been in practice 1 year. He is one of 8 doctors at Boston Children's Hospital and one of 111 doctors at Memorial Sloan Kettering Cancer Center who specialize in Radiation Oncology. He has more than 50 publications and over 500 citings.
Education & Training
Massachusetts General HospitalInternship, Preliminary Year, 2015 - 2016
Yale School of MedicineClass of 2015
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology
Certifications & Licensure
FL State Medical License 2023 - Present
NY State Medical License 2020 - 2026
NJ State Medical License 2020 - 2025
MA State Medical License 2015 - 2022
American Board of Radiology Radiation Oncology
Clinical Trials
- A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain Start of enrollment: 2022 Jun 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas.Haley K Perlow, David R Raleigh, Tony J C Wang, Erqi L Pollom, Michael T Milano
International Journal of Radiation Oncology, Biology, Physics. 2025-05-01 - A balancing ACT: maximizing the benefits of appropriate brain radiation therapy.Divya Yerramilli, Luke R G Pike, James Janopaul-Naylor
The Lancet Regional Health. Europe. 2025-05-01 - Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.Luke R G Pike, Helena Yu, Chad G Rusthoven
JAMA Oncology. 2025-04-03
Press Mentions
Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part II)September 18th, 2024- Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part I)September 5th, 2024
- MSK Research Highlights, August 13, 2024August 13th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
